PTGS1 and COVID-19: In the genesis of COVID-19, there is a process of endotheliitis associated with thrombotic changes, but no studies have reported the use of acetylsalicylic acid (ASA), a well-known antiplatelet agent that acts by inhibiting cyclooxygenase 1 (COX-1)4, as a possible therapeutic approach.